Furegrelate sodium salt is primarily investigated for its role as a thromboxane synthase inhibitor. This property makes it significant in medical research, particularly in studies focused on cardiovascular diseases. By inhibiting thromboxane synthase, it reduces the production of thromboxane A2, a compound known for promoting platelet aggregation and vasoconstriction. This mechanism is explored for potential therapeutic applications in conditions like thrombosis, myocardial infarction, and stroke, where controlling platelet activity and improving blood flow are crucial. Additionally, its effects are studied in inflammatory and pulmonary conditions, as thromboxane A2 is also involved in inflammation and bronchoconstriction. Research continues to evaluate its efficacy and safety in these areas.